Objective: Gonadotropin-releasing hormone agonists induce a state of hypogonadotropic hypogonadism eradicating the symptomatology in women affected by premestrual syndrome. Unfortunately Gonadotropin-releasing hormone agonist administration frequently causes unpleasant side-effects consisting of climacteric-like symptoms. The association of steroid hormones may prevent hypoestrogenic symptoms without reducing the effectiveness of the Gonadotropin-releasing hormone agonist treatment. The aim of this study was to evaluate the treatment of premenstrual syndrome with a Gonadotropin-releasing hormone agonist in association with tibolone, a synthetic compound structurally related to noretinodrel having weak estrogenic, androgenic and progestogen properties. Methods: Eight patients affected by premenstrual syndrome (aged 23-29 years; mean age ± SD, 25.3 ± 2.9) were enrolled and treated for two cycles with leuprolide acetate depot (3.75 mg i.m. every 28 days) and tibolone (2.5 mg every day per os). The efficacy of treatment was evaluated using a visual analogue scale. The mean severity of each symptom and sign was evaluated during the last 9 days of treatment compared with the last 9 days of the cycle preceding treatment. Results: Mean scores for each of the adverse psychological/physical and positive psychological symptoms (p <0.05) improved significantly during treatment. Conclusions: Our study shows that tibolone administered in association with Gonadotropin-releasing hormone agonists does not reduce the therapeutic effect of Gonadotropin-releasing hormone agonists in women affected by premenstrual syndrome. In this way, tibolone used in association with Gonadotropin-releasing hormone agonists may provide long-term medical treatment for women with premenstrual syndrome.
|Number of pages||4|
|Journal||Italian Journal of Gynaecology and Obstetrics|
|Publication status||Published - 1999|
- Gonadotropin-releasing hormone agonist
- Premenstrual syndrome
ASJC Scopus subject areas
- Obstetrics and Gynaecology